Search company, investor...

Affectis Pharmaceuticals

affectis.com

Founded Year

2002

Stage

Series D | Alive

Total Raised

$29.8M

Last Raised

$4.2M | 13 yrs ago

About Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

Headquarters Location

Kraepelinstrasse 2

80804,

Germany

Missing: Affectis Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Affectis Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Affectis Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Affectis Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Affectis Pharmaceuticals Patents

Affectis Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/24/2012

8/26/2014

Clusters of differentiation, Ion channels, G protein coupled receptors, Immunology, Cytokines

Grant

Application Date

7/24/2012

Grant Date

8/26/2014

Title

Related Topics

Clusters of differentiation, Ion channels, G protein coupled receptors, Immunology, Cytokines

Status

Grant

Latest Affectis Pharmaceuticals News

Charcot-Marie-Tooth Disease Type I A Drug Market : Trends, Strategy, Applications Analysis and Growth by 2022

Aug 23, 2018

HTF MI broadcasted a new title “Global Charcot-Marie-Tooth Disease Type I A Drug Market Research Report 2018” with 109 pages and in-depth assessment including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players such as Addex Therapeutics Ltd, Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA & …. The research study provides forecasts for Charcot-Marie-Tooth Disease Type I A Drug investments till 2022. Get Access to sample pages @  https://www.htfmarketreport.com/sample-report/945162-global-charcot-marie-tooth-disease-type-i-a-drug-market   Product Analysis: This Report provides a detailed study of given products. The report also provides comprehensive analysis of Key Trends & advance technologies. The Global Charcot-Marie-Tooth Disease Type I A Drug (Thousands Units) and Revenue (Million USD) Market Split by Product Type such as ADX-71441, AFC-5128 & Others Application Analysis: This report provides an advance approach to the market growth with a detailed analysis of the overall competitive scenario of the Global Charcot-Marie-Tooth Disease Type I A Drug market. The market is segmented by Application such as Hospital, Clinic & Others with historical and projected market share and compounded annual growth rate. Industry Growth: An in-depth study about key trends and emerging drivers with market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, shares, trend and strategies for Charcot-Marie-Tooth Disease Type I A Drug market. The market is expected to estimate at XX million by 2023 growing at a CAGR of XX%. Read Detailed Index of full Research Study at @  https://www.htfmarketreport.com/reports/945162-global-charcot-marie-tooth-disease-type-i-a-drug-market Key Highlights of the Global Charcot-Marie-Tooth Disease Type I A Drug Market : • Market Share of players that includes Addex Therapeutics Ltd, Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA & … to better understand how deeply they have penetrated the market. • Conceptual analysis of the Charcot-Marie-Tooth Disease Type I A Drug Market products, application wise segmented study. • Clear study and pin-point analysis for changing competitive dynamics • Analysis of major regional segmentation on the basis of how the market is predicted to grow Key questions answered in this comprehensive study – Global Charcot-Marie-Tooth Disease Type I A Drug Market Research Report 2018  What will the market size be in 2023 and what will the growth rate be? What are the key market trends? What is driving Global Charcot-Marie-Tooth Disease Type I A Drug Market? What are the challenges to market growth? Who are the key vendors in Global Charcot-Marie-Tooth Disease Type I A Drug Market space? What are the key market trends impacting the growth of the Global Charcot-Marie-Tooth Disease Type I A Drug Market? What are the key outcomes of the five forces analysis of the Global Charcot-Marie-Tooth Disease Type I A Drug Market? What are the market opportunities and threats faced by the vendors in the Global Charcot-Marie-Tooth Disease Type I A Drug market? Get in-depth details about factors influencing the market shares of the North America, Europe, China, Japan, Southeast Asia & India? Enquire for customization in Report @  https://www.htfmarketreport.com/enquiry-before-buy/945162-global-charcot-marie-tooth-disease-type-i-a-drug-market There are 15 Chapters to display the Global Charcot-Marie-Tooth Disease Type I A Drug market. Chapter 1, to describe Definition, Specifications and Classification of Global Charcot-Marie-Tooth Disease Type I A Drug, Applications of , Market Segment by Regions; Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of , Capacity and Commercial Production Date, Manufacturing Plants Distribution, Export & Import, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, China, Japan, Southeast Asia & India, Segment Market Analysis (by Type) [ADX-71441, AFC-5128 & Others]; Chapter 7 and 8, to analyze the Change Management Software Segment Market Analysis (by Application [Hospital, Clinic & Others]) Major Manufacturers Analysis; Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type [ADX-71441, AFC-5128 & Others], Market Trend by Application [Hospital, Clinic & Others]; Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, to analyze the Consumers Analysis of Global Charcot-Marie-Tooth Disease Type I A Drug by region, type and application; Chapter 12, to describe Charcot-Marie-Tooth Disease Type I A Drug Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15, to describe Charcot-Marie-Tooth Disease Type I A Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source. Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. About Author: HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”. Contact US : HTF Market Intelligence Consulting Private Limited Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 sales@htfmarketreport.com

Affectis Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Affectis Pharmaceuticals Rank

Affectis Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Affectis Pharmaceuticals founded?

    Affectis Pharmaceuticals was founded in 2002.

  • What is Affectis Pharmaceuticals's latest funding round?

    Affectis Pharmaceuticals's latest funding round is Series D.

  • How much did Affectis Pharmaceuticals raise?

    Affectis Pharmaceuticals raised a total of $29.8M.

  • Who are the investors of Affectis Pharmaceuticals?

    Investors of Affectis Pharmaceuticals include Bayern Kapital, EQT Life Sciences, EMBL Ventures, KfW, Aescap Venture and 5 more.

  • Who are Affectis Pharmaceuticals's competitors?

    Competitors of Affectis Pharmaceuticals include Mast Therapeutics, BioMarck Pharmaceuticals, FORUM Pharmaceuticals, Bioceros, Probiodrug and 16 more.

Compare Affectis Pharmaceuticals to Competitors

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

N
Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

I
Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

D
Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.